TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00732810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m\^2 IV on Day 1 of each 21 day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m\^2 IV on Day 1 of each 21 day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m\^2 IV on Day 1 of each 21 day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m\^2 IV on Day 1 of each 21 day cycle until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1250 mg/m\^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150 mg orally once daily until disease progression.
Study: NCT01076712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Interventions
Description: Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill

Intervention type: OTHER
Group type: OTHER
Intervention: Education Classes
Description: Education Classes
Study: NCT01536431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro insulin peptide
Description: Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pro insulin peptide
Description: Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
Study: NCT04280367

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardised semi-structured talk
Description: Comprehensive assessment of at-risk mental states (CAARMS) will be used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardised semi-structured talk
Description: Comprehensive assessment of at-risk mental states (CAARMS) will be used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardised semi-structured talk
Description: Comprehensive assessment of at-risk mental states (CAARMS) will be used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Autistic spectre disorder screening
Description: Autism-spectrum quotient (AQ) auto-questionnaire will be used.
Study: NCT02704156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberknife plus Pembrolizumab and Trametinib
Description: Radiation therapy plus drug

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyberknife plus Gemcitabine
Description: Radiation therapy plus drug
Study: NCT00605605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 120 mg/day, single once daily dose taken after breakfast by oral route
Study: NCT03009123

Intervention type: OTHER
Intervention: Erectile dysfunction
Description: Patients with ED are considered belonging to the exposure group.
Study: NCT04280367

Intervention type: DIAGNOSTIC_TEST
Intervention: Autistic spectre disorder screening
Description: Autism-spectrum quotient (AQ) auto-questionnaire will be used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Autistic spectre disorder screening
Description: Autism-spectrum quotient (AQ) auto-questionnaire will be used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Anxiety measuring
Description: An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: Anxiety measuring
Description: An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: Anxiety measuring
Description: An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
Study: NCT05209022

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: 140 mL of beetroot juice or beetroot juice placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice
Description: 140 mL of beetroot juice or beetroot juice placebo
Study: NCT00620438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine-artemether and nevirapine
Description: Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumefantrine-artemether and efavirenz
Description: Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine-artemether and rifampicin
Description: Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
Study: NCT03023033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth messaging
Description: SMS appointment reminders and health messaging via mobile phones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transport Payments
Description: A payment scaled to reflect the cost of typical return transport fare for residents of the clinic catchment area
Study: NCT01499251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 Dose Escalation
Description: Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
Study: NCT02240615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinopsys Lacrimal Stent
Description: Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
Study: NCT04110210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Ultrasound-Guided Erector Spinae Plane Block
Description: Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Consumption
Description: After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
Study: NCT01499251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1b
Description: Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ancillary Study
Description: Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
Study: NCT02896712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management (CM)
Description: The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo capsule will be filled with corn starch and riboflavin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo capsule will be filled with corn starch and riboflavin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.
Study: NCT01379157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
Study: NCT01113879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching
Description: Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
Study: NCT01988116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Calcitriol 0.5 mcg once daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03385252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Eggs provided as complementary food for the infant

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visits
Description: Twice weekly household visits by study staff

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visits
Description: Twice weekly household visits by study staff
Study: NCT00891137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human myeloid progenitor cells
Description: Single intravenous injection/infusion
Study: NCT02941835

Intervention type: RADIATION
Group type: OTHER
Intervention: pre-operative irradiation
Description: pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
Study: NCT03573830

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transport Canada material
Description: The current Transport Canada booster seat education material focuses on imparting guidelines; that is, it describes, in plain language, the minimum and maximum ages, heights, and weights to determine when a child should use a booster seat, and when it is safe for a child to use only the seat belt. This material does not describe the principle of operation of seat belts (i.e., redirecting crash forces to the rib cage and pelvis), nor the principle of operation of booster seats (i.e., ensuring the seat belt is placed correctly across the chest and hips).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced material
Description: Enhancements to the booster seat education material were developed based on the hypothesis that parents would better appreciate the additional injury risk reduction afforded by booster seats, if they understand that: (1) seat belts prevent injuries by redirecting crash forces to stronger parts of the body (i.e., rib cage and pelvis); and (2), without booster seats, children would wear the seat belt on their abdomen and neck, which directs crash forces to more vulnerable anatomical structures (i.e., internal organs and spine).
Study: NCT00891137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human myeloid progenitor cells
Description: Single intravenous injection/infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human myeloid progenitor cells
Description: Single intravenous injection/infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human myeloid progenitor cells
Description: Single intravenous injection/infusion
Study: NCT01499888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Non-Myeloablative Stem Cell Transplantation
Description: Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.~Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
Study: NCT01321775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
Description: Neo-adjuvant doses (12 weeks):~Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.~Adjuvant doses:~Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)
Study: NCT02753699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Intervention of interest; follow-up after ALV-active study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Intervention of interest; follow-up after ALV-active study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Intervention of interest; follow-up after ALV-active study
Study: NCT02051530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tryptophan depletion
Description: tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tryptophan depletion
Description: tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
Study: NCT02408016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02097316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JewelPump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JewelPump
Study: NCT02408016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03214809

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound protocol
Description: after first assessment and treatment by the MET team, an Multi-organ ultrasound protocol will be run by the MET doctor
Study: NCT02418858

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation surgery
Description: Deep Brain Stimulation surgery awake vs. asleep

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation surgery
Description: Deep Brain Stimulation surgery awake vs. asleep
Study: NCT05492669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride, Injectable
Description: In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
Study: NCT02408016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT02847364

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
Study: NCT02730234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JetStream XC with balloon angioplasty
Description: JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
Study: NCT00989417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTIVATION of HOME MONITORING
Description: Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVATION of HOME MONITORING
Description: Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
Study: NCT01577446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac resynchronization therapy
Description: Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
Study: NCT00237146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT02104232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THPP-I

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EUC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EUC
Study: NCT00529594

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (Control Group)
Description: Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib (Treatment Group)
Description: Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
Study: NCT04047264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: Undergo microdialysis
Study: NCT04104009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Following the randomization process, group education of pregnant women will be conducted through four one-hour meetings.~Education program: teaching about the basics of childbirth physiology, visit to the maternity ward with the aim of reducing the fear of childbirth, applying the deep inhale and exhale exercise in the first birth stage, applying the classical music listening technique that will continue until the end of pregnancy daily (in the evenings before bedtime) (for 15 minutes), teaching and applying techniques for successful breastfeeding, maternal and infant health care after delivery. The training program will be implemented so that after 4 workshops a 5-week break will be taken. At the end of the program, the educator arranges with the respondents a weekly telephone check (for the sake of communication quality) to inform them of adherence to the agreed classical music listening.Pregnant women who do not meet expectations will be excluded from the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No education
Description: In the control group there will be no education, no breathing exercises and no listening to classical music.
Study: NCT03480997

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate and Ipratropium Bromide

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate
Study: NCT01538862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony Stimulating Factor (GCSF)
Description: G-CSF 10mcg/kg/d SQ for 7 days